Petri Huhtinen, PhD, Optomed’s Clinical Director manages company’s clinical study portfolio
ensuring that clinical view is in the core of company’s strategy. Furthermore, he works closely with
Optomed’s AI-partners who are using retinal images to develop AI algorithms for various disorders.
Dr Huhtinen has been involved in numerous screening projects and programs for more than 15
years. The focus of the programs has varied between eye disease, cancer and various congenital
disease. Geographical distribution has been wide, ranging from South-East Asia to Americas, and
from Sub-Saharan Africa to the Nordic Counties. During the years with screening Huhtinen has
become a big fan of preventive healthcare where successful and cost-efficient screening plays a key
role.
Dr Huhtinen holds PhD in in vitro diagnostics, MSc in biochemistry and BBA in information systems
science.
Day 1 - 17 October 2022
| Time |
Session |
|
|
14:00
16:00
|
The R&D to commercialisation route for digital health solutions are very challenging. How do aspiring Nordic innovators and researchers minimise risks to ensure higher chances of commercial success? A Case-Sharing session by the Nordic Companies on their journey to success
-
Early detection of breast cancer with cutting edge technology
-
Automated individual analysis and decision support for diabetes teams and patients
-
Innovative and affordable solutions that enable effective diabetes and cancer screening
-
A reliable solution for arrhythmia monitoring no matter where you are
-
Cost-effective sensors that enable continuous monitoring of patients at home
-
Transforming the screening and management of diabetic eye disease
-
Panel Discussion
|
